Tumor-specific circulating cell-free DNA (cfDNA) BRAF mutations (muts) to predict clinical outcome in patients (pts) treated with the BRAF inhibitor dabrafenib (GSK2118436).
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: The University of Sydney, Westmead Hospital, Melanoma Institute Australia, Westmead Institute, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Angeles Clinic and Research Institute, Assistance Publique – Hôpitaux de Paris, California Pacific Medical Center, University of California, Los Angeles, Essen University Hospital, Abramson Cancer Center, University of Pennsylvania, Charité – Universitätsmedizin Berlin, GlaxoSmithKline (United States)
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2550399249